About Us

Humanetics is a privately held, advanced clinical-stage pharmaceutical company headquartered in Minnesota with satellite offices located in Arizona, North Carolina, Pennsylvania, and Texas. The Company was founded in 1988 and is engaged in the development and commercialization of new drugs to protect and treat against bodily harm caused by exposure to radiation, chemical agents, and biological threats.

The Company’s flagship drug is BIO 300, which was initially discovered and developed by the U.S. Department of Defense to protect warfighters against battlefield injuries caused by exposure to radiation (e.g., nuclear detonation, terrorist activities). The Company expanded this original drug use to include prevention of damage caused by cancer radiation therapy and pulmonary inflammation resulting from biological and chemical agents. Humanetics has four open Investigational New Drug (IND) applications covering these indications, each supported by an active clinical program. Our focus continues to be on medical countermeasures for warfighters and for improving the treatment outcomes for patients receiving radiation treatment of solid tumors as well as patients with pulmonary inflammation and fibrotic disease.

The Company's scientific team has strong partnerships with private and public research institutions that have unique capabilities to evaluate its drug products. Click here to learn more about our collaboration partners. Funding for our programs has come from private equity sources as well as multiple government appropriations, grants, and contracts across several federal agencies. Humanetics has received non-dilutive funding from the Department of Defense (DoD), the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Heart, Lung, and Blood Institute (NHLBI), the Biomedical Advanced Research and Development Authority (BARDA), the National Space Biomedical Research Institute (NSBRI), and the National Aeronautics and Space Administration (NASA).